Targeted therapy of renal cell cancer

Current Opinion in Investigational Drugs

Volumn 9, Issue 6, 2008, Pages 570-575

  Wysocki, P J ^a   Zolnierek, J ^b   Szczylik, C ^b   Mackiewicz, A ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b MILITARY INSTITUTE OF MEDICINE   (Poland)

Author keywords

Renal cell cancer; Sorafenib; Sunitinib; Targeted therapy; Temsirolimus

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; ERLOTINIB; EVEROLIMUS; GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LENALIDOMIDE; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VON HIPPEL LINDAU PROTEIN;

ADD ON THERAPY; ADVANCED CANCER; ANEMIA; ANGIOGENESIS; ASTHENIA; BONE LESION; BONE METASTASIS; CANCER IMMUNOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TARGETING; DRUG TREATMENT FAILURE; FATIGUE; HAND FOOT SYNDROME; HISTOPATHOLOGY; HOARSENESS; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; INFECTION; KIDNEY CANCER; KIDNEY CARCINOMA; LOW DRUG DOSE; LYMPHOCYTOPENIA; MOLECULAR BIOLOGY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHRECTOMY; NEUTROPENIA; PANCREATITIS; PERIPHERAL EDEMA; PROGNOSIS; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUMOR VASCULARIZATION; UPREGULATION; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CYTOKINES; DRUG DELIVERY SYSTEMS; HUMANS; KIDNEY NEOPLASMS; PROGNOSIS;

EID: 44649097842     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Lipworth L, Tarone RE, McLaughlin JK: The epidemiology of renal cell carcinoma. J Urol (2006) 176(6 Pt 1):2353-2358. • This review provides detailed and up-to-date information on RCC epidemiology.
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ: Cancer statistics, 2006. CA Cancer J Clin (2006) 56(2):106-130.
3. SEER Cancer Statistics Review, 1973-1999: National Cancer Institute. Bethesda, MD, USA (2002). http://seer.cancer.gov/csr/1973_1999/
4. Linehan W: Genetic basis of renal cell carcinoma: Disease-specific approaches to therapy. American Society of Clinical Oncology, Educational Book (2005):362-367.
5. Halbert RJ, Figlin RA, Atkins MB, Bernal M, Hutson TE, Uzzo RG, Bukowski RM, Khan KD, Wood CG, Dubois RW: Treatment of patients with metastatic renal cell cancer: A RAND Appropriateness Panel. Cancer (2006) 107(10):2375-2383.
6. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR Jr, Munshi N, Crawford ED: Nephrectomy followed by interferon α-2b compared with interferon α-2b alone for metastatic renal-cell cancer. N Engl J Med (2001) 345(23):1655-1659.
7. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R: Radical nephrectomy plus interferon-α-based immunotherapy compared with interferon α alone in metastatic renal-cell carcinoma: A randomised trial. Lancet (2001) 358(9286):966-970.
8. McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP et al: Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 23(1):133-141.
9. Wysocki PJ, Zolnierek J, Szczylik C, Mackiewicz A: Recent developments in renal cell cancer immunotherapy. Expert Opin Biol Ther (2007) 7(5):727-737. • This review provides an up-to-date review of immunotherapeutic strategies in RCC.
10. Motzer RJ, Bander NH, Nanus DM: Renal-cell carcinoma. N Engl J Med (1996) 335(12):865-875.
11. Interferon-α and survival in metastatic renal carcinoma: Early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet (1999) 353(9146):14-17.
12. Small EJ, Weiss GR, Malik UK, Walther PJ, Johnson D, Wilding G, Kuzel T, Bajamonde A, Paton V: The treatment of metastatic renal cell carcinoma patients with recombinant human γ interferon. Cancer J Sci Am (1998) 4(3):162-167.
13. Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Fyfe G: High-dose aldesleukin in renal cell carcinoma: Long-term survival update. Cancer J Sci Am (1997) 3(Suppl 1):S70-S72.
14. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. J Am Med Assoc (1994) 271(12):907-913.
15. Rosenberg SA, Yang JC, White DE, Steinberg SM: Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: Identification of the antigens mediating response. Ann Surg (1998) 228(3):307-319.
16. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, Liewehr DJ et al: Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol (2003) 21(16):3127-3132.
17. Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T et al: Recombinant human interleukin-2, recombinant human interferon α-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med (1998) 338(18):1272-1278.
18. Escudier B: Advanced renal cell carcinoma: Current and emerging management strategies. Drugs (2007) 67(9):1257-1264.
19. Latif F, Tory K, Gnarra J, Yao M, Duh FM, Orcutt ML, Stackhouse T, Kuzmin I, Modi W, Geil L et al: Identification of the von Hippel-Lindau disease tumor suppressor gene. Science (1993) 260(5112):1317- 1320.
20. Kim WY, Kaelin WG: Role of VHL gene mutation in human cancer. J Clin Oncol (2004) 22(24):4991-5004. • This paper describes the role of the VHL gene in RCC.
21. Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW: Activation of HIF1α ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc Natl Acad Sci USA (2000) 97(19):10430-10435.
22. Hay N: The Akt-mTOR tango and its relevance to cancer. Cancer Cell (2005) 8(3):179-183.
23. Jiang BH, Liu LZ: PI3K/PTEN signaling in tumorigenesis and angiogenesis. Biochim Biophys Acta (2008) 1784(1):150-158.
24. Bardos JI, Ashcroft M: Hypoxia-inducible factor-1 and oncogenic signalling. Bioessays (2004) 26(3):262-269.
25. Yu Y, Sato JD: MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor. J Cell Physiol (1999) 178(2):235- 246.
26. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, Abraham RT: Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol Cell Biol (2002) 22(20):7004-7014.
27. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z et al: Temsirolimus, interferon a, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 356(22):2271-2281. •• This study represents the first treatment to significantly prolong overall survival of metastatic RCC patients.
28. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M: Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol (2002) 20(1):289-296.
29. Chow LQ, Eckhardt SG: Sunitinib: From rational design to clinical efficacy. J Clin Oncol (2007) 25(7):884-896. • This paper provides a description of sunitinib's mechanisms of action and clinical efficacy.
30. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP et al: Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol (2006) 24(1):25-35.
31. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE, Li JZ et al: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 24(1):16-24.
32. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I et al: Sunitinib versus interferon α in metastatic renal-cell carcinoma. N Engl J Med (2007) 356(2):115-124.
33. Motzer RJ, Figlin RA, Hutson TE, Tomczak P, Bukowski RM, Rixe O, Bjarnason GA, Kim ST, Chen I, Michaelson D: Sunitinib versus interferon-α (IFN-α) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors. Proc Am Soc Clin Oncol (2007) 25(18 Suppl):Abs 5024.
34. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS et al: Sunitinib in patients with metastatic renal cell carcinoma. J Am Med Assoc (2006) 295(21):2516-2524.
35. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R, Bukowski RM: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst (2007) 99(1):81-83. • This article explains the mechanism of sunitinib-induced fatigue in RCC patients.
36. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E et al: Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 24(16):2505-2512.
37. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F et al: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 356(2):125-134. • This paper provides results of a phase III trial of sorafenib in advanced mRCC.
38. Szczylik C, Demkow T, Staehler M, Rolland F, Negrier S, Hutson TE, Bukowski RM, Scheuring UJ, Burk K, Escudier B: Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: Final results. Proc Am Soc Clin Oncol (2007) 25(18 Suppl):Abs 5025.
39. Mancuso MR, Davis R, Norberg SM, O'Brien S, Sennino B, Nakahara T, Yao VJ, Inai T, Brooks P, Freimark B, Shalinsky DR et al: Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest (2006) 116(10):2610-2621.
40. Rugo HS, Herbst RS, Liu G, Park JW, Kies MS, Steinfeldt HM, Pithavala YK, Reich SD, Freddo JL, Wilding G: Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: Pharmacokinetic and clinical results. J Clin Oncol (2005) 23(24):5474-5483.
41. Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC et al: Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: A phase II study. Lancet Oncol (2007) 8(11):975-984.
42. Wang Y, Fei D, Vanderlaan M, Song A: Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis (2004) 7(4):335-345.
43. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med (2003) 349(5):427-434.
44. Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A: Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol (2005) 23(31):7889- 7896.
45. Bukowski R, Kabbinavar F, Figlin R, Flaherty K, Srinivas S, Vaishampayan U, Drabkin HA, Dutcher J, Ryba S, Xia Q, Scappaticci FA et al: Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol (2007) 25(29):4536-4541.
46. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V et al: Bevacizumab plus interferon α-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet (2007) 370(9605):2103-2111.
47. Merchan JR, Liu G, Fitch T, Picus J, Qin R, Pitot HC, Maples W, Erlichman C: Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results. Proc Am Soc Clin Oncol (2007) 25(18 Suppl):Abs 5034.
48. Bracarda S, Porta C, Boni C, Santoro A, Artioli F, Di Bartolomeo C, Contu A, Gasparro D, De Angelis V, Caserta C, GOIRC Study Group: Randomized prospective phase II trial of two schedules of sorafenib daily and interferon-α2a (IFN) in metastatic renal cell carcinoma (RAPSODY): GOIRC Study 0681. Proc Am Soc Clin Oncol (2007) 25(18 Suppl):Abs 5100.
49. Gollob J, Richmond T, Jones J, Rathmell WK, Grigson G, Watkins C, Peterson B, Wright J: Phase II trial of sorafenib plus interferon-α 2b (IFN-α2b) as first- or second-line therapy in patients (pts) with metastatic renal cell cancer (RCC). Proc Am Soc Clin Oncol (2006) 24(18 Suppl):Abs 4538.
50. Ryan CW, Goldman BH, Lara PN, Beer TM, Drabkin HA, Crawford E: Sorafenib plus interferon-α2b (IFN) as first-line therapy for advanced renal cell carcinoma (RCC): SWOG 0412. Proc Am Soc Clin Oncol (2006) 24(18 Suppl):Abs 4525.
51. Hipp MM, Hilf N, Walter S, Werth D, Kanz L, Weinschenk T, Singh H, Brossart P: Sorafenib but not sunitinib affects the induction of immune responses. J Clin Oncol (2007) 25(18 Suppl):Abs 3504.
52. Atzpodien J, Royston P, Wandert T, Reitz M: Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer (2003) 88(3):348-353.
53. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol (1999) 17(8):2530-2540.
54. Négrier S, Escudier B, Gomez F, Douillard JY, Ravaud A, Chevreau C, Buclon M, Pérol D, Lasset C: Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: A report from the Groupe Français d'Immunothérapie. Ann Oncol (2002) 13(9):1460-1468.
55. Choueiri TK, Garcia JA, Elson P, Khasawneh M, Usman S, Golshayan AR, Baz RC, Wood L, Rini BI, Bukowski RM: Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer (2007) 110(3):543-550. • This study identified novel clinical factors for predicting outcome in patients treated with VEGF-targeted therapies.